A UK based biotechnology company developing small molecule therapeutics against highly validated targets
omass.comUKBiotechFounded 2016
6 sources · checked 2 times, last 28m ago
Source 4 reports the value of Syncona’s holding, not OMass’s company valuation. Source 3’s approximately $475 million figure is total funding raised, not this round’s amount.
3 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release distinguishes the £10 million extension investment from the £85.5 million total raised in the Series B round.
2 sources
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $310M ~$475M to date | 2026-10-14 | Bain Capital Life Sciences, Forbion, Novo Holdings | 5 outlets. #56 in Trending |
6 sources · checked 2 times, last 28m ago [ VERIFIED · CORRECTED ] read against 4 of 6 sources
Source 4 reports the value of Syncona’s holding, not OMass’s company valuation. Source 3’s approximately $475 million figure is total funding raised, not this round’s amount. | ||||
OMass Therapeutics discovers and develops small-molecule medicines for patients with rare and immunological diseases by studying drug targets in their native molecular surroundings with mass spectrometry.
Checked against 12 sources today
| Series B ext. Series B extension [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.5M £85.5M financing total £10 million | 2023-05-15 | not stated | No recent discussion |
3 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 3 sources The release distinguishes the £10 million extension investment from the £85.5 million total raised in the Series B round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]3 pages read: omass.com, thebaehq.com, uktech.news·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 3 sources·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2022-04-28 | GV (Google Ventures), Northpond Ventures, Sanofi Ventures | No recent discussion |
2 sources [ VERIFIED ] read against 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: omass.com, globenewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $18.0M £14 million | 2018-11-20 | Syncona | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: omass.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||